<DOC>
	<DOCNO>NCT00005879</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use LY353381 may effective way prevent development breast cancer woman hyperplasia . PURPOSE : Randomized phase II trial study effectiveness LY353381 prevent breast cancer woman hyperplasia .</brief_summary>
	<brief_title>LY353381 Preventing Breast Cancer Women With Hyperplasia</brief_title>
	<detailed_description>OBJECTIVES : - Determine LY353381 hydrochloride improve baseline cytology woman high risk breast cancer . - Determine drug modulate potential surrogate endpoint biomarkers drug effect biomarkers . - Determine cytologic improvement associate initial presentation various stratification factor . - Determine whether cytology correlate potential surrogate endpoint biomarkers drug effect biomarkers whether change cytology correlate change biomarkers . - Monitor effect drug term quality life woman 's health . OUTLINE : This randomize , double-blind , multicenter study follow open-label study arm . Patients stratify accord cytologic status ( hyperplasia atypia v hyperplasia without atypia ) , mutation status ( know carrier BRCA1 BRCA2 gene vs know carrier mutant gene ) , menopausal status ( premenopausal v postmenopausal ) , estrogen-receptor status , participate center . Patients randomize one two treatment arm . - Arm I : Patients receive oral LY353381 hydrochloride daily 6 month . - Arm II : Patients receive oral placebo daily 6 month . Patients arm receive oral LY353381 hydrochloride additional 6 month . Quality life assess baseline 6 12 month . Patients follow 2 week annually 5 year . PROJECTED ACCRUAL : A total 210-220 patient accrue study within 2.5-3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Estrogen Receptor Modulators</mesh_term>
	<mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Current random fine needle breast aspiration ( FNA ) evidence 1 following : Hyperplasia atypia Hyperplasia without atypia 10year modify Gail risk least 4 % Hyperplasia without atypia BRCAPRO risk least 25 % Hyperplasia without atypia know mutation BRCA1 BRCA2 Hyperplasia without atypia history contralateral ductal carcinoma situ invasive breast cancer FNA must take day 114 menstrual cycle premenopausal woman Classified ACR class IIII mammogram stepwedge within past 6 month If intact uterus and/or ovary , must color doppler transvaginal pelvic sonogram within past 6 month show endometrial thickening great 13 mm premenopausal great 8 mm postmenopausal No ovarian cyst felt possibly probably nonphysiologic resolve gynecologist 's satisfaction repeat sonogram Must agree genetic counseling genetic testing perform BRCA1 BRCA2 No active cancer ( e.g. , detectable disease ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Any Performance status : Not specify Life expectancy : At least 12 month Hematopoietic : Hemoglobin great 10 g/dL Granulocyte count great 1,000/mm^3 No deficiency protein C , protein S , antithrombin III No activate protein C resistance Hepatic : Albumin great 3.0 g/dL Bilirubin le 1.5 mg/dL AST le 100 U/L Alkaline phosphatase le 200 U/L Renal : Creatinine le 1.5 mg/dL Cardiovascular : No history deep venous thrombosis relate trauma pregnancy No severe coronary artery disease No history prior stroke Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No active cancer No retinal vein thrombosis No concurrent severe poorly control migraine No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY : Biologic therapy : At least 12 month since prior immunotherapy Chemotherapy : At least 3 month completion prior KUMC phase II difluoromethylornithine ( DFMO ) study baseline aspiration At least 12 month since prior chemotherapy Endocrine therapy : Must start stop hormone replacement therapy oral contraceptive within 6 month baseline aspiration Must continue hormone replacement therapy and/or oral contraceptive take time baseline aspiration At least 12 month since prior tamoxifen , raloxifene , antihormonal therapy Radiotherapy : At least 3 month since prior radiotherapy Surgery : At least 6 month prior oophorectomy baseline aspiration Other : At least 2 week since start new medication would ingest 1 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast cancer</keyword>
</DOC>